Now let me run the calibration search (bracketing round) to compare with anchor papers:Let me read a few anchor papers in full:Now let me do the narrowing search within the bracket range of 5–7:Now I have enough to write my final review. Let me compile everything.

---

## Summary

CBGBench proposes a comprehensive benchmark for structure-based drug design (SBDD) that unifies five tasks — de novo generation, linker design, fragment growing, side-chain decoration, and scaffold hopping — under a single 3D graph completion formulation ("fill in the blank"). The paper categorizes 12 methods along three dichotomies (voxelized vs. continuous, one-shot vs. autoregressive, domain-knowledge vs. data-driven), re-evaluates them under controlled training conditions, introduces novel evaluation metrics (LBE, PLIP-based interaction pattern JSD/MAE, geometry clash ratio), and validates conclusions on real-world GPCR targets. The principal empirical findings — that CNN-based methods remain highly competitive and that current domain-knowledge incorporation yields limited gains — are grounded in systematic data.

---

## Strengths

1. **Unified graph-completion formulation across five tasks** (Section 2.1, Figure 1): Recasting de novo generation and all four lead optimization tasks as instances of `p(G|C,P)` enables principled transfer of methods across tasks and provides a clean formal framework. This is the paper's most original conceptual contribution.

2. **Systematic re-evaluation of 12 methods under controlled conditions** (Table 1, Sections 3–5): Fixing GNN architecture (GVP for autoregressive, EGNN for diffusion), training iterations (5M), and docking software (AutoDock Vina) addresses documented inconsistencies in the prior literature (e.g., GraphBP using a different data split, DiffBP using Gnina). This is the core value of a benchmark contribution.

3. **Extended evaluation protocol with novel metrics** (Section 4): The introduction of LBE (normalizing Vina energy by atom count to remove molecule-size confound), PLIP-based interaction pattern JSD/MAE (per-pocket and overall), bond-length/angle JSD, and cross-clash ratio substantially expands beyond the standard QED/SA/Vina triplet and addresses known deficiencies in prior evaluation. The LBE motivation is well-grounded in cited literature on size–affinity confounds.

4. **Non-obvious empirical findings** (Tables 2–5): The result that CNN-based LiGAN and VoxBind remain highly competitive in interaction metrics — outperforming many recent diffusion models — and that domain-knowledge methods (DecompDiff, D3FG) do not consistently outperform pure data-driven ones are genuine, evidence-backed insights rather than confirmations of expectations.

5. **Extension to four lead optimization subtasks with curated datasets** (Table 6, Section 3): Building Linker/Fragment/Side-chain/Scaffold datasets from Crossdocked2020 splits and adapting 6 continuous-position methods to these tasks represents meaningful engineering contribution that broadens the benchmark beyond de novo generation.

6. **Real-world target validation** (Section 5.3, Figures 5–6): Applying pretrained models to ADRB1 and DRD3 with t-SNE fingerprint visualization and Vina/LBE distributions provides external corroboration that benchmark rankings generalize beyond the held-out CrossDocked set.

---

## Weaknesses

### Fatal
None.

### Major

1. **Test sets for lead optimization tasks are too small for reliable ranking conclusions.** Table 6 shows linker: 43, fragment: 61, side chain: 64, scaffold: 64 test instances. For a benchmark whose stated purpose includes ranking methods, differences of 1–2 pockets can reverse method orderings with only 43 test pockets. The Friedman ranking reported for lead optimization subtasks (Table 7) is presented without any rank-stability analysis (e.g., bootstrap confidence intervals or jackknife resampling). Since Crossdocked2020 contains many more pocket-ligand pairs that could in principle be included, the restriction to these small counts appears to follow de novo conventions not designed for multi-task benchmarking. This weakens confidence in the comparative conclusions for lead optimization specifically.

2. **Inconsistent training protocols between model families for lead optimization create an unqualified confounder.** Section 5.2 explicitly states: autoregressive models are fine-tuned from de novo checkpoints for 1,000,000 iterations, while one-shot diffusion models are trained from scratch (because the zero-CoM technique shifts center). This asymmetry is disclosed but never quantified. Autoregressive models thus arrive with implicit knowledge from large-scale de novo pre-training; diffusion models do not. Cross-family comparisons in Tables 7–8 are therefore not cleanly interpretable, and the paper's conclusions (e.g., "MolCraft maintains good performance") require the caveat that diffusion models were at a structural training disadvantage in the lead optimization subtasks.

### Minor

1. **No justification or sensitivity analysis for the interaction weight (0.4) in the overall ranking.** Table 5 weights interaction at 0.4 and each of the other three aspects at 0.2. No rationale is provided beyond the implicit assumption that binding is most important. A sensitivity check showing whether the top-three overall rankings (MolCraft, TargetDiff, LiGAN) are stable under reasonable weight perturbations would significantly strengthen the overall ranking claim.

2. **Per-method validity rates are not reported.** Section 4 mentions that each method generates fewer than 10,000 molecules after validity filtering but does not report per-method validity rates as a metric. A method generating 5% valid molecules that score well on those 5% is behaviorally quite different from one generating 90% valid molecules. Reporting this directly would sharpen interpretability of all subsequent tables.

3. **PLIP analysis applied to docked conformations without an explicit quality-filter disclosure.** PLIP-based interaction pattern analysis (JSD/MAE) is applied after AutoDock Vina docking, but the paper does not explicitly state whether geometrically malformed or invalid molecules are filtered before PLIP analysis. Methods that generate structurally invalid molecules may receive nonsensical PLIP outputs that affect their interaction pattern scores.

### Trivial
None that are not already covered above.

---

## Nice-to-Haves

- **Rank-stability analysis for lead optimization subtasks**: Repeating Friedman rankings over bootstrap samples of the 43–64 test pockets and reporting variance would directly address the reliability concern without expanding the dataset.
- **Integration of DRD3 case-study results in main text**: DRD3 results appear to be in the appendix; showing that rankings are consistent across both GPCR targets would strengthen generalizability claims.
- **At least one sensitivity variant of the 0.4 interaction weight**: Even one alternate weighting (e.g., equal weights across four aspects) shown to preserve top rankings would be reassuring.
- **Training-condition ablation for diffusion models on lead optimization**: If even one diffusion model could be warm-started from a de novo checkpoint with a CoM correction, it would let the authors quantify the magnitude of this asymmetry.

---

## Removed Points

*These points are flagged to be removed, treat them with caution.*

- **Harsh Critic, Weakness 3 (Domain-knowledge methods absent from lead optimization)**: The paper provides an explicit engineering rationale ("different tasks require different priors," "voxelized methods are not easily extended") and labels it future work. This is a reasonable scoping decision, not a methodological flaw. The criticism that DecompDiff's arm-scaffold decomposition should have been adapted for side-chain and scaffold tasks is speculative about engineering feasibility. DEMOTED to Nice-to-Have.

- **Harsh Critic, "Case study on real-world targets only shows ADRB1"**: Section 5.3 explicitly mentions both ADRB1 and DRD3, with DRD3 in the appendix. Criticizing this as a weakness when both targets are addressed is a scope-creep concern. REMOVED.

- **Harsh Critic, "Strengthening the Paper" section (third point about DRD3)**: DRD3 is already included; this point misread the paper. REMOVED.

- **Strength Finder, "Open-sourced unified framework"**: While mentioned in the paper, this is stated but not directly verifiable from the paper content alone. Retained as a minor supporting point but not counted as a primary strength.

---

## Novel Insights

The most genuinely novel insight synthesized across both reviewers is the **empirical inversion of expected capability ordering**: CNN/voxel-based methods (LiGAN, VoxBind) — architecturally older and conceptually simpler than recent equivariant diffusion approaches — outperform many newer methods in the interaction dimension, ranking 1st and 5th overall. This inverts the common narrative that expressivity improvements in GNNs automatically translate to better molecular design. The paper traces this to CNNs' advantage in perceiving many-body spatial patterns within a single filter (cited to Atom3D), a mechanistic explanation that, if correct, has implications for 3D GNN architecture design. The secondary finding — that domain-knowledge incorporation in DecompDiff and D3FG does not consistently help and sometimes hurts — further complicates the field's narrative that physically-motivated priors are straightforwardly beneficial.

---

## Suggestions

1. **Expand lead optimization test sets** from 43–64 to at least 150+ instances per task by pulling additional pocket-ligand pairs from Crossdocked2020; report Friedman rank confidence intervals via bootstrap resampling.
2. **Explicitly report per-method validity rates** per task as a column in the main tables; this changes interpretation of all subsequent metric values.
3. **Add a sensitivity analysis** for the 0.4 interaction weight using at least two alternate weighting schemes; confirm top-3 rankings are stable.
4. **Quantify the training asymmetry** in at least one experiment: train one diffusion model from scratch vs. warm-started (with CoM correction) on a lead optimization task to bound the magnitude of the confounder.
5. **Clarify whether a conformation quality filter** is applied before PLIP analysis in the evaluation pipeline.

---

## Score and Decision

**Calibration anchors:**

| Path | Avg Score | Round | Comparison to CBGBench |
|---|---|---|---|
| `/RyWypcIMiE.md` | 6.50 | R1+R2 | Narrower scope (evaluation metrics only for SBDD); CBGBench covers 5 tasks, 12 methods, open codebase, broader eval — comparable quality but CBGBench has more weaknesses (small test sets, training asymmetry) |
| `/8DLVrWL78S.md` | 4.00 | R1 | Weak baseline; CBGBench substantially more comprehensive and better supported |
| `/8jKuUHsndT.md` | 5.50 | R2 | Benchmark re-evaluation (Syntheseus for retrosynthesis); similar structure but CBGBench covers more tasks and metrics — CBGBench is better |
| `/NSDszJ2uIV.md` | 6.33 | R2 | Molecular conformer ensemble benchmark; CBGBench comparable in scope; similar strengths and weaknesses |
| `/9qS3HzSDNv.md` | 6.20 | R1 | Novel SBDD model paper; CBGBench is a benchmark paper with broader scope but no novel model |
| `/g3VCIM94ke.md` | 6.67 | R1 | Strong SBDD generative model paper; CBGBench's contribution is different (benchmark vs. model) |
| `/KSLkFYHlYg.md` | 8.00 | R1 | High-quality novel model paper; CBGBench does not reach this level |
| `/NSVtmmzeRB.md` | 8.00 | R1 | Strong novel model paper; CBGBench is clearly below this |

**Round 1 bracket**: 5.0–7.0

**Round 2 narrowing**: The closest analogues are RyWypcIMiE (6.50) and NSDszJ2uIV (6.33), both evaluation/benchmark papers in adjacent domains. CBGBench is broader than RyWypcIMiE but has more significant methodological concerns (small test sets for its primary lead optimization comparison, training asymmetry that affects cross-family comparisons). Syntheseus (5.50) is slightly weaker in scope. CBGBench sits between Syntheseus and RyWypcIMiE, leaning closer to RyWypcIMiE given the genuine engineering scope and novel empirical findings.

**Final score**: The training asymmetry (Major) and small test sets (Major) are real but not fatal — the de novo benchmarking is on solid ground and the framework's infrastructure contribution stands regardless of ranking reliability on 43-sample tasks. The paper makes a real, needed contribution to SBDD evaluation. I place it at **6.0**.

MY FINAL SCORE: <score>6.0</score>
MY FINAL DECISION: <decision>Accept</decision>